Overview

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Status:
RECRUITING
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
Phase:
PHASE1
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborator:
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.